Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

On the basis of strong preclinical rationale, we sought to confirm recommended phase II dose (RP2D) for olaparib, a PARP inhibitor, combined with the AKT inhibitor capivasertib and assess molecular markers of response and resistance. We performed a safety lead-in followed by expansion in endometrial...

Celý popis

Podrobná bibliografie

Vydáno v:	Clinical cancer research Ročník 27; číslo 23; s. 6354
Hlavní autoři:	Westin, Shannon N, Labrie, Marilyne, Litton, Jennifer K, Blucher, Aurora, Fang, Yong, Vellano, Christopher P, Marszalek, Joseph R, Feng, Ningping, Ma, XiaoYan, Creason, Allison, Fellman, Bryan, Yuan, Ying, Lee, Sanghoon, Kim, Tae-Beom, Liu, Jinsong, Chelariu-Raicu, Anca, Chen, Tsun Hsuan, Kabil, Nashwa, Soliman, Pamela T, Frumovitz, Michael, Schmeler, Katheleen M, Jazaeri, Amir, Lu, Karen H, Murthy, Rashmi, Meyer, Larissa A, Sun, Charlotte C, Sood, Anil K, Coleman, Robert L, Mills, Gordon B
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.12.2021
Témata:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Female Humans Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Phthalazines Piperazines Pyrimidines Pyrroles Triple Negative Breast Neoplasms - drug therapy
ISSN:	1557-3265, 1557-3265
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!